D.E. Shaw’s 2025 Scorecard: Put on Quite a Show With AI and Quants
D.E. Shaw put on a quant-powered show in 2025 — and quietly built a private-credit fortress for what comes next.
AQR Capital’s 2025 Scorecard: From Applied Quantitative Research to Actually Quality Returns
AQR Capital’s machines finally had their year. Strong 2025 returns across quant strategies prove factors aren’t dead — they just needed faster computers.
Pershing Square Rounds Up a Strong 2025: High Conviction, Concentrated Bets — and Real Outperformance
Pershing Square’s concentrated, high-conviction strategy paid off in 2025. Fewer bets, bigger opinions — and real outperformance.
Berkshire Hathaway's 2025 Scorecard: Defensive Portfolio, Slightly Underwhelming Performance — But a Historic Transition
Berkshire played defense in 2025: record cash, cautious positioning, and the end of an era as Warren Buffett stepped aside. Solid, sober, and very Berkshire.
Elliott’s 2025 Paradox: Why the Parachute Cost Them the Party
While Wall Street partied through an AI-fueled bull market, Elliott Management showed up wearing a parachute. The result was underperformance — by design. Here’s why Paul Singer’s 2025 wasn’t a failure, but a strategic bet on what comes next.
Renaissance Technologies in 2025: Quant Quake, Post-Simons Growing Pains & The Limits of the Machine
Even the smartest hedge fund on Earth can stumble. Renaissance Technologies’ public funds struggled in 2025 as quant models collided with narrative-driven markets, policy shocks, and momentum chaos. A fascinating reminder that machines learn — sometimes the hard way.
Principles of Prosperity: How Bridgewater’s AI-Driven “Machine” Built a Fortress in 2025
After years of skepticism, Bridgewater roared back in 2025. Pure Alpha surged, All Weather delivered, and Ray Dalio’s machine pivoted hard into U.S. equities and AI infrastructure. Fortress rebuilt — with a few cracks worth watching.
Citadel’s 2025 Scorecard: No Fireworks, Just Relentless Discipline
Citadel delivered another disciplined year in 2025 — not flashy, but formidable. Here’s what Ken Griffin’s fortress is really doing, and what it means for investors.
Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring
CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯
Fundamental Research–Driven Fund Voss Capital Buys PAR Technology: Time to Shop?
PAR Technology is shifting from legacy hardware to a unified restaurant SaaS platform. After Voss Capital’s $7.1M buy, massive institutional ownership, and heavy short interest, the setup looks like an inflection-point story—high upside if execution clicks, sharp downside if it doesn’t.